Patents by Inventor Roland Jan ARENDS

Roland Jan ARENDS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-SIRP ? antibodies
    Patent number: 11718681
    Abstract: The invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention also relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapies.
    Type: Grant
    Filed: February 2, 2022
    Date of Patent: August 8, 2023
    Assignee: Byondis B.V.
    Inventors: Gijsbertus Franciscus Maria Verheijden, Gerard Rouwendal, Roland Jan Arends, Timo Kars Van Den Berg, Hanke Lottie Matlung, Katarina Franke
  • ANTI-SIRP ALPHA ANTIBODIES
    Publication number: 20220195063
    Abstract: The invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention also relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapies.
    Type: Application
    Filed: February 2, 2022
    Publication date: June 23, 2022
    Inventors: Gijsbertus Franciscus Maria VERHEIJDEN, Gerard ROUWENDAL, Roland Jan ARENDS, Timo Kars VAN DEN BERG, Hanke Lottie MATLUNG, Katarina FRANKE
  • Anti-SIRP? antibodies
    Patent number: 11274159
    Abstract: The present invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention further relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapeutics. The anti-SIRPalpha antibodies described are more specific than known anti-SIRPalpha antibodies, whereas they show excellent affinity for both SIRPalpha1 and SIRPalphaBIT. In one embodiment the anti-SIRPalpha antibodies do not bind to SIRPgamma. In a second embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPbeta1v1. In a third embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPeta1v2. In a fourth embodiment, the anti-SIRPalpha antibodies do not bind to SIRPbeta1v1.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: March 15, 2022
    Assignee: Byondis B.V.
    Inventors: Gijsbertus Franciscus Maria Verheijden, Gerard Rouwendal, Roland Jan Arends, Timo Kars Van Den Berg, Hanke Lottie Matlung, Katarina Franke
  • ANTI-SIRP ALPHA ANTIBODIES
    Publication number: 20210070874
    Abstract: The present invention relates to antibodies against SIRP? that are suitable for use in anti-cancer therapy. The invention further relates to the use of the anti-SIRP? antibodies in the treatment of human solid tumours and haematological malignancies, optionally in combination with other anti-cancer therapeutics. The anti-SIRPalpha antibodies described are more specific than known anti-SIRPalpha antibodies, whereas they show excellent affinity for both SIRPalpha1 and SIRPalphaBIT. In one embodiment the anti-SIRPalpha antibodies do not bind to SIRPgamma. In a second embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPbeta1v1. In a third embodiment, the anti-SIRPalpha antibodies do not bind to SIRPgamma and do not bind to SIRPeta1v2. In a fourth embodiment, the anti-SIRPalpha antibodies do not bind to SIRPbeta1v1.
    Type: Application
    Filed: May 15, 2018
    Publication date: March 11, 2021
    Inventors: Gijsbertus Franciscus Maria VERHEIJDEN, Gerard ROUWENDAL, Roland Jan ARENDS, Timo Kars VAN DEN BERG, Hanke Lottie MATLUNG, Katarina FRANKE